NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, one of the nation’s largest specialty infusion pharmacies focused on rare diseases, has announced the addition of UPLIZNA to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering.
By adding UPLIZNA to its extensive portfolio of life-saving specialty therapies, BioTek reMEDys is furthering its commitment to respond to the needs of and requests of patients and their loved ones. UPLIZNA is a prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
NMOSD, also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). For these patients, UPLIZNA is proven to help reduce relapses that could lead to permanent disabilities.
“The clinical evidence surrounding UPLIZNA in the treatment of NMOSD patients has been overwhelmingly positive,” said Carla Sparkler, BioTekreMEDys’ Chief Marketing Officer. “We are proud to have access to this limited distribution drug and to care for this patient population.”
Effective immediately, UPLINZA will be available at all BioTek reMEDys locations.
Founded in 2011, BioTek reMEDys, based in New Castle, DE, has become one of the nation’s largest independent infusion pharmacies focused on home infusion and infusion suites. Chai Gadde opened the pharmacy to meet the specific needs of patients who require specialty medications. BioTek reMEDys and its affiliates are now licensed to operate in all 50 states. For information visit www.biotekrx.com.